| Document |
Document Title |
|
WO/2020/223811A1 |
Pharmaceutical formulations are provided that include at least two antibiotically active ingredients: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); a sesquiterpene that is one or...
|
|
WO/2020/223800A1 |
A formulation for pain management is described for use by individuals experiencing pain. The formulation comprises a plurality of cannabinoids in optimized amounts to manage pain. One or more excipient, diluent or carrier is included in ...
|
|
WO/2020/224327A1 |
A method of using magnetic nano material to purify plant anthocyanin. The prepared magnetic nano material has a particle size of 10-600 nm, and can effectively adsorb a coloring agent and enhance the stability thereof. Using a magnetic n...
|
|
WO/2020/220218A1 |
The present invention relates to a compound having the structure of formula (1) below, a product containing the compound, a preparation method therefor and the use thereof in γ-glutamyl transpeptidase detection.
|
|
WO/2020/220141A1 |
Transdermal cannabinoid formulations comprising a versatile cannabinoid stock provided as a variety of cosmetic delivery systems providing enhanced cannabinoid absorption, and more controlled release into vascular and/or lymphatic system...
|
|
WO/2020/223536A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
|
|
WO/2020/223538A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
|
|
WO/2020/218680A1 |
The present invention relates to a novel organic light emitting compound and an organic electroluminescent diode using same and, more specifically, to: a compound having excellent thermal stability, electrochemical stability, light emitt...
|
|
WO/2020/215164A1 |
Provided herein are methods and compositions for neuroprotection. The neuroprotective composition can be or include cannabinol or a derivative thereof. The neuroprotective composition can be used in the treatment of a neurodegenerative d...
|
|
WO/2020/218600A1 |
A composition for forming optical components which contains a compound represented by formula (0). (In formula (0), X represents an oxygen or sulfur atom or represents a non-bridged state, the R0 moieties are each independently an option...
|
|
WO/2020/219686A1 |
A method to prepare and/or isolate water soluble anthocyanins is provided.
|
|
WO/2020/218599A1 |
A compound represented by formula (0). (In formula (0), each R0 independently represents an optionally substituted alkyl group having 1-30 carbon atoms, an optionally substituted aryl group having 6-30 carbon atoms, an optionally substit...
|
|
WO/2020/219687A1 |
A cannabis processing system comprises a grinding apparatus and a cell disruption apparatus. The grinding apparatus is configured to grind wet cannabis cuttings to from a ground, wet cannabis material comprising wet cannabis particles ha...
|
|
WO/2020/211786A1 |
Disclosed are a microencapsulation method for improving the stability of anthocyanin, a product therefrom and the use thereof. The method for preparing an anthocyanin microcapsule comprises: (1) using sodium alginate as a wall material, ...
|
|
WO/2020/209035A1 |
A compound represented by formula (1). R1 is, for example, an alkyl having 1-15 carbon atoms; ring A1 and ring A2 are 1,4-phenylene, etc.; a is 2, etc.; b and c are 0, 1, or 2; Z1 is a single bond, etc.; P1 and P2 are polymerizable group...
|
|
WO/2020/210246A1 |
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical composi...
|
|
WO/2020/209205A1 |
The present invention addresses the problem of providing a compound having high photobase generation efficiency. This carbamoyloxime compound is represented by general formula (I) (in the formula, A represents an aromatic ring-containing...
|
|
WO/2020/176741A9 |
Provided are methods of treating multiple sclerosis, which comprises administering to a patient a therapeutically effective amount of DNA methylation blocker. Also provided are method of retarding development of multiple sclerosis by adm...
|
|
WO/2020/205465A1 |
The present invention generally relates to a composition matter useful for diagnosis and treatment of Alzheimer's disease comprising A-L-F or a pharmaceutically acceptable salt thereof, wherein A is beta-amyloid peptide or a fragment the...
|
|
WO/2020/201610A1 |
The present invention relates to the spiro-heterocyclic compounds of general formula (I), wherein: n is selected from 0, 1 and 2; G is selected from C and N; A is a heteroatom selected from O, S, N, NH and NRi, wherein Ri is selected fro...
|
|
WO/2020/198876A1 |
The specification relates to a process for preparation of a compound of Formula (II), the process involving the step of reacting a compound of Formula (I), in a solvent, in the presence of a solid supported acid catalyst to form the comp...
|
|
WO/2020/205683A1 |
In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL...
|
|
WO/2020/197983A1 |
An improved process for producing various types of cannabis extract from harvested cannabis wherein a quantity of harvested cannabis, which typically includes the inflorescence, floral leaves, and small stems of a flowering cannabis plan...
|
|
WO/2020/194237A1 |
Methods of rapidly inhibiting efflux from a cell, sensitizing a drug-resistant cell to a drug and treating a subject with a drug-resistant pathology, by administering tetrahydrocannabinolic acid (THCa), cannabidiol (CBD) or a combination...
|
|
WO/2020/197828A1 |
The present disclosure provides a novel process for the continuous extraction, purification and production of a flavan-3-ol extract from early harvested whole grape clusters. The final product from this process is particularly rich in mo...
|
|
WO/2020/194936A1 |
The present invention addresses the problem of providing a method for producing refined oils and fats whereby the content of, e.g., glycidol, can be reduced and reductions in the content of tocopherols can be inhibited, and providing a m...
|
|
WO/2020/191098A1 |
A process for producing cannabis extracts from milled cannabis material by extracting with cold ethanol. The cannabis material is immersed in a tank of cold ethanol (14). Solvent is removed from the extracted material and recycled (20). ...
|
|
WO/2020/183370A1 |
Systems and methods for indicating an effect onset period of a cannabis product including an effect onset device having a timing mechanism to track the effect onset period. The effect onset device including a processor having an activati...
|
|
WO/2020/186077A1 |
The present disclosure relates to molecularly imprinted polymers that target cannabinoid(s), including THC and CBD, as well as methods of making molecularly imprinted polymers that target cannabinoid(s), including THC and CBD and uses th...
|
|
WO/2020/186165A1 |
The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
|
|
WO/2020/186110A1 |
Various compounds and pharmaceutically acceptable salts thereof are provided capable of binding cyclin-dependent kinase inhibitor 1B. The compounds can have a structure according to Formula I or Formula II as detailed herein. The compoun...
|
|
WO/2020/178053A1 |
Phenol derivatives of general formula (I) and (II), wherein meanings of the substituents are indicated in the description, their pharmaceutically acceptable salts, together with the processes for their preparation, their use as antimicro...
|
|
WO/2020/168421A1 |
The invention provides cyclodextrin inclusion complexes of cannabis extracts, cannabinoids and cannabis terpenes, and methods of making such complexes. The cyclodextrin inclusion complexes include a host and guest compounds. The host may...
|
|
WO/2020/165902A1 |
The present invention provides methods of extraction of at least one cannabinoid from an initial cannabis biomass in "one-pot" step using toluene to form a toluene extract and using the toluene extract for producing high concentrations o...
|
|
WO/2020/165715A1 |
Methods and systems for generating a cannabis-based therapy including an inhalable cannabis derived compound are disclosed. The methods and systems include a patient portal and a server having a matching system stored there, on the match...
|
|
WO/2020/163637A1 |
The present invention concerns novel compounds useful in the treatment of cancer, particularly including compounds linking a bisphosphonate moiety with KBU2046, and pharmaceutically acceptable salts, co-crystals, polymorphs, solvates, hy...
|
|
WO/2020/159019A1 |
The present invention relates to a novel organic light-emitting compound and an organic electroluminescent device using same and, more specifically, to a compound having excellent thermal stability, electrochemical stability, light-emitt...
|
|
WO/2020/156345A1 |
The present invention relates to the technical field of biomedicine, and specifically relates to a PSMA inhibitor, a compound and an application. The PSMA inhibitor having a novel core structure as provided by the present invention has v...
|
|
WO/2020/153279A1 |
This invention relates to a method for preparing a desired isomer of a substituted 2-trifluoromethyl-2H-chromene-3-carboxylic acid, which is characterized by comprising: (a) contacting the substituted 2-trifluoromethyl-2H-chromene-3-carb...
|
|
WO/2020/154434A1 |
Provided are compositions and methods comprising agonists. Also disclosed are agonist compounds, pharmaceutical compositions of agonists, and methods of using the same.
|
|
WO/2020/153669A1 |
The present invention relates to a compound for an organic electric device, an organic electric device using same, and an electronic apparatus thereof. According to the present invention, high luminous efficiency, low driving voltage, an...
|
|
WO/2020/148354A1 |
The present invention provides novel compounds having the general formula: (I) wherein R1 to R10, Gi, G2 and m are as described herein, compositions including the impounds and methods of using the compounds for the treatment of hepatitis B.
|
|
WO/2020/145282A1 |
The purpose of the present invention is to provide a production method or the like that enables obtaining of a composition containing isoxanthohumol with high isoxanthohumol yield and efficiency. The present invention pertains to a produ...
|
|
WO/2020/144897A1 |
The purpose of the present invention is to provide a production method or the like that enables obtaining of a composition containing isoxanthohumol with high isoxanthohumol yield and efficiency. The present invention pertains to a produ...
|
|
WO/2020/135872A1 |
Provided are a drug, a pharmaceutical composition, or a pharmaceutical kit for immunosuppression, for the treatment of conditions such as psoriasis, comprising a forskolin derivative or a salt thereof and optionally a prostaglandin compo...
|
|
WO/2020/134138A1 |
The present disclosure relates to the technical field of luminescent materials, and relates in particular to an organic electroluminescent compound, a preparation method therefor and an organic electroluminescent device. In order to solv...
|
|
WO/2020/138147A1 |
The present invention provides a compound which has a condensed skeleton of an aromatic compound represented by formula (1-1) and an aromatic aldehyde represented by formula (2-1). (In formula (1-1), A represents an aromatic ring; each R...
|
|
WO/2020/132618A1 |
A photocleavable heterobifunctional linker can include a structure of Formula (A) wherein coumarin is any coumarin or coumarin derivative; R, R9, and R10 are each independently a chemical moiety; R1 is a hydrogen, protecting group, leavi...
|
|
WO/2020/128767A1 |
The invention relates to compositions comprising water-soluble complexes of a-cyclodextrin (alpha-cyclodextrin) and cannabinoids and/or complexes of a-cyclodextrin and cannabis-derived terpenes, methods of making these a-cyclodextrin com...
|
|
WO/2020/130120A1 |
The present invention pertains to a novel cancer metastasis inhibitor. According to the present invention, a cancer metastasis inhibitor, which is characterized by comprising as an active ingredient a compound represented by formula (I) ...
|
